Screening of microbes, isolation, genetic manipulation, and physiological optimization of Brevibacterium helvolum to produce and excrete thymidine and deoxyuridine in high concentrations
Sk. Kalirai et al., Screening of microbes, isolation, genetic manipulation, and physiological optimization of Brevibacterium helvolum to produce and excrete thymidine and deoxyuridine in high concentrations, J GEN A MIC, 46(4), 2000, pp. 217-224
Analogues of deoxypyrimidines are used in the treatment of a variety of hum
an ailments. Azidothymidine, or AZT, is one such analogue used to treat AID
S. Thymidine is the precursor of AZT, and its cost contributes to the high
price of AZT, Attempts are being made to isolate and genetically manipulate
microbes that can produce and excrete this compound in high concentrations
. To this end, 145 different microbial species from Zeneca and the American
Type Culture Collection were screened, Moreover, soil samples were collect
ed from 36 different sites in England, and microbes from these samples were
isolated and screened. From approximately 25,000 isolates screened as sing
le colonies and from 4,000 in liquid cultures, a strain of Brevibacterium h
elvolum showed the most promising results. Pyrimidine metabolic pathways of
this bacterium were worked out, the isolate was genetically manipulated, a
nd physiological conditions were optimized to increase the production of th
ymidine and deoxyuridine. These mutants of B. helvolum are considered to be
of commercial importance.